Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen with Methotrexate-Based GvHD Prophylaxis

Sandy On, Walter Domingo, Edna Cheung, Laura Johnston

Blood (2023) 142 (Supplement 1): 6952.

https://doi.org/10.1182/blood-2023-182983

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Blood (2023) 142 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2023-188162

Published: 2023

Journal Articles

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Blood (2021) 137 (17): 2321–2325.

https://doi.org/10.1182/blood.2020009432

Published: 2021

Includes: Supplemental data

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

Consolidative CD8 + Memory T-Cell Donor Lymphocyte Infusion Augments Donor Chimerism with a Low Risk of Gvhd Following Matched Related Donor Hematopoietic Cell Transplantation

Michael A. Spinner, MD, Lori S. Muffly, MD MS, Sally Arai, MD, Laura Johnston, MD, Everett H. Meyer, MD PhD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Andrew R. Rezvani, MD, Judith A. Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Samuel Strober, MD, Robert Lowsky, MD

Blood (2017) 130 (Supplement 1): 2003.

https://doi.org/10.1182/blood.V130.Suppl_1.2003.2003

Published: 2017

Journal Articles

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia

Paul A. Carpenter, Laura Johnston, Hugo F. Fernandez, Jerald P. Radich, Michael J. Mauro, Mary E. D. Flowers, Paul J. Martin, Theodore A. Gooley

Blood (2017) 130 (9): 1170–1172.

https://doi.org/10.1182/blood-2017-03-771121

Published: 2017

Includes: Supplemental data

Journal Articles

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Laura Johnston, MD, Randall Armstrong, Jeanette Baker, PhD, Bita Sahaf, Joanne Otani, Keri Tate, PhD, Cynthia Tudisco, Kevin Sheehan, PhD, Everett Meyer, MD PhD, David Miklos, MD PhD, Robert S. Negrin, MD

Blood (2016) 128 (22): 385.

https://doi.org/10.1182/blood.V128.22.385.385

Published: 2016

Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Blood (2016) 128 (22): 505.

https://doi.org/10.1182/blood.V128.22.505.505

Published: 2016

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Blood (2015) 126 (23): 3232.

https://doi.org/10.1182/blood.V126.23.3232.3232

Published: 2015

Journal Articles

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Wen-Kai Weng, MD PhD, Randall Armstrong, Sally Arai, MD, Laura Johnston, MD, Ginna G. Laport, MD, Robert Lowsky, MD, David B. Miklos, Judith A. Shizuru, MD PhD, Jonathan E. Benjamin, Robert S. Negrin, MD, Sunil Reddy, MD, Lynn Million, MD, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2014) 124 (21): 2544.

https://doi.org/10.1182/blood.V124.21.2544.2544

Published: 2014

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

Jonathan Benjamin, MD, PhD, Ginna G Laport, MD, Keri Tate, PhD, Leah Galvez, RN, Randall Armstrong, Kevin Sheehan, PhD, Sally Arai, MD, Robert Lowsky, MD, Laura Johnston, MD, David B. Miklos, MD, PhD, Judith Shizuru, PhD, MD, Wen-Kai Weng, MD, PhD, Robert Negrin, MD

Blood (2013) 122 (21): 899.

https://doi.org/10.1182/blood.V122.21.899.899

Published: 2013

Journal Articles

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.

Jonathan Benjamin, MD, PhD, Saurabh Chhabra, MD, Holbrook E Kohrt, MD, PhD, Ginna G Laport, MD, Sally Arai, MD, Laura Johnston, MD, David B Miklos, MD, PhD, Judith A. Shizuru, MD, PhD, Wen-Kai Weng, MD, PhD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2012) 120 (21): 3087.

https://doi.org/10.1182/blood.V120.21.3087.3087

Published: 2012

Journal Articles

Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia

Jonathan A Rose, MS, Tamara J. Dunn, MD, Michaela Liedtke, MD, Paul Elson, ScD, Matt Kalaycio, MD, Ed Copelan, MD, Ronald Sobecks, MD, Mikkael A. Sekeres, MD, MS, Sean Hobson, Laura Johnston, MD, Shawnda Tench, Sharisa Cross, Anjali Advani, MD

Blood (2012) 120 (21): 1472.

https://doi.org/10.1182/blood.V120.21.1472.1472

Published: 2012

Journal Articles

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

Corey Cutler, MD, MPH, FRCPC, Brent R. Logan, PhD, Ryotaro Nakamura, MD, Laura Johnston, MD, Sung W. Choi, M.D., David L Porter, MD, William J Hogan, MBBCh, Marcelo C Pasquini, MD, MS, Margaret L. MacMillan, MD, John R. Wingard, MD, Edmund K. Waller, MD, PhD, Stephan A. Grupp, MD, PhD, Philip L. McCarthy, MD, Juan Wu, MS, Zhenhuan Hu, MPH, Shelly L Carter, ScD, Mary M. Horowitz, MD, MS, Joseph H. Antin, MD

Blood (2012) 120 (21): 739.

https://doi.org/10.1182/blood.V120.21.739.739

Published: 2012

NARROW

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen with Methotrexate-Based GvHD Prophylaxis

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Consolidative CD8 + Memory T-Cell Donor Lymphocyte Infusion Augments Donor Chimerism with a Low Risk of Gvhd Following Matched Related Donor Hematopoietic Cell Transplantation

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility

Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.

Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia

Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only